EMEA-003234-PIP01-22 - paediatric investigation plan

oleclumab

Key facts

• Active Substance:
  oleclumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0388/2022
• PIP number:
  EMEA-003234-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  • Treatment of lung cancer
  • Treatment of pancreatic cancer
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  AstraZeneca AB

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  09/09/2022

Decision

P/0388/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for oleclumab (EMEA-003234-PIP01-22)

Reference Number: EMA/675740/2022